Skip to main content
. 2005 Oct 20;115(11):2979–2991. doi: 10.1172/JCI23298

Figure 4.

Figure 4

The effect of Cl2MDP-LIPs on IL-1β–induced angiogenesis. (A) FACS analysis of infiltrating cells on day 6, in IL-1β–implanted corneas from BALB/c mice that received Cl2MDP-LIPs or PBS-LIPs i.v. and/or s.c. The cells were stained with PE-CD11b mAb and FITC–Gr-1 or FITC-F4/80 mAb. (B) Corneal neovascularization at the indicated time points in BALB/c mice receiving Cl2MDP-LIPs or PBS-LIPs i.v. and/or s.c. The percentages of infiltrating cells in IL-1β–implanted corneas of Cl2MDP-LIP– or PBS-LIP–treated mice were 4.75% ± 0.48% (i.v., CD11b+F4/80+), 13.2% ± 4.03% (i.v., CD11b+Gr-1+), 1.63% ± 0.30% (i.v. + s.c., CD11b+F4/80+), and 6.61% ± 0.93% (i.v. + s.c., CD11b+Gr-1+). (C) Neovascularization was quantified by area in mm2 on day 4 (white bars) and day 6 (black bars). Bars show means ± SD of independent experiments (n = 3 or 4; *P < 0.01 and **P < 0.05 versus PBS-LIPs). (D) Corneal neovascularization induced with VEGF at the indicated time points after receiving Cl2MDP-LIPs or PBS-LIPs (i.v. + s.c.). (E) Quantitative analysis of neovascularization on day 6. VEGF-induced corneal neovascularization in mice (n = 6) receiving Cl2MDP-LIPs was inhibited compared with mice (n = 6) receiving PBS-LIPs. *P < 0.01 using the Student’s t test.